Palisade Bio (PALI) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
PALI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Palisade Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$2.59 |
| 52 Week Low | US$0.53 |
| Beta | 1.64 |
| 1 Month Change | -3.59% |
| 3 Month Change | 139.37% |
| 1 Year Change | 28.74% |
| 3 Year Change | -97.24% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Palisade Bio: Gut Prodrug For IBD With Catalysts
Dec 23Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Shareholder Returns
| PALI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 17.5% | 1.7% | 1.3% |
| 1Y | 28.7% | 27.1% | 15.8% |
Return vs Industry: PALI exceeded the US Biotechs industry which returned 27.1% over the past year.
Return vs Market: PALI exceeded the US Market which returned 15.8% over the past year.
Price Volatility
| PALI volatility | |
|---|---|
| PALI Average Weekly Movement | 23.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PALI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PALI's weekly volatility has increased from 17% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | J. Finley | www.palisadebio.com |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company’s lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn’s disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
Palisade Bio, Inc. Fundamentals Summary
| PALI fundamental statistics | |
|---|---|
| Market cap | US$327.81m |
| Earnings (TTM) | -US$11.23m |
| Revenue (TTM) | n/a |
Is PALI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PALI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.23m |
| Earnings | -US$11.23m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.6% |
How did PALI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 00:30 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Palisade Bio, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jason McCarthy | Maxim Group |